HAVCR2 and neoplasm: With anti-TIM-3, we observed a potent dose-dependent increase in the cytotoxicity of SUDHL10-primed compared to Raji-primed T cells against Raji cells (Figure 3E, 3F), despite both sets of tumor-primed T cells being TIM-3+ by flow cytometry (Figure 3D).